乳腺癌术前辅助化疗后原发肿瘤临床改变与预后

Neoadjuvant Chemotherapy of Breast Cancer.It's Response and Prognosis

1971年1月～1982年12月,我院应用秋水仙硷制剂及CU方案术前辅助治疗可观察的乳腺癌390例,疗效达到CR18例,PR101例,SD259例,PD12例。5年生存率有效组(CR+PR)与无效组(SD+PD)分别为77.3％及65.7％(P=0.01),10年生存率两组分别为56.4％及50.9％(P=0.2)。肿瘤对化疗药物愈敏感,预后愈好,尤其是CR,腋结转移率为33.3％,5及10年生存率为94.4％及90.9％。当采用CU联合化疗时,原发瘤T_3,临床Ⅲ期及腋结转移时,5及10年生存率有效组较无效组有所提高,表明术前化疗对晚期病人可以改善预后。

During January 1971 to December 1982,390 cases of breast cancer were treated by colchicine derivative and ure- phatine as a neoadjuvant protocol in the author's hospital. Of this series, 18 achieved CR, 101 PR,259 SD,and 12 cases PD. The 5-year survival rates of responded groups (CR+PR)and non-responsive groups (SD+PD) were 77.3% and 65.7% respectively (P=0.01). The 10-year survival rates of these two groups were 56.4% and 50.9% respectively (P=0. 2). Sensitive tumour responded to chemothcrapy had better prognosis,particularly in cases with CR. The rate of axillary involvement was 33.3%,the 5-year and 10-year survival rates were 94.4% and 90.9% respectively. Under the protocol of CU, patients with T_3 tumors stage Ⅲ disease and positive axillary lymphnodes the 5-year and 10-year sur- vival rates of responsive patients were better than non-responsive groups.It is demonstrated that neoadjuvant chemothera- py is able to improve the outcome of breast cancer of advanced stage.